It’s not your average Joe anymore. The heavyweights-those holding between 100 and 1,000 BTC-are scooping up more than 10K BTC daily. Plus, ETF holdings are hitting a staggering 620K BTC ($76.9B). This is the era of whales, not retail. 🐋💰
Clickbait title: Something like “OMG, $555M Tokens Unlocking: Altcoin Rally Ruined or What? 😂” Make it under 100 chars.<|reserved_50|>
Yeah, you guessed it. The US government shutdown, alongside some other tiny little problems in the world economy, had investors running back to crypto like it’s the last lifeboat on the Titanic.
Brace yourselves, folks. $0.89 might just decide where Cardano is going next. Think of it as the cliffhanger before the grand finale. 👀
For years, Pfizer has waged its internal battles, launching an array of new medicines with the hopes of rekindling growth. Yet, like many before them, these medicines, while clinically sound, have failed to bring forth the kind of profits their creators had envisaged. There is, however, a sense that the company has turned a corner, perhaps inadvertently, in its pursuit of the elusive next great pharmaceutical treasure. In a bold move, Pfizer has acquired Metsera, a biotech firm specializing in weight management therapies, for the substantial sum of $5 billion. The acquisition is a calculated gamble, one that could either lift the company from its current stagnation or plunge it deeper into uncertainty.
Mastercard’s market cap is a cool $525 billion, which, I gotta admit, is impressive. But let’s put that into perspective. Since it went public in 2006, its stock price has skyrocketed over 12,000%. Yeah, you read that right. But lately? Eh, it’s down 4% since the end of August. So, here’s the big question: Is this dip an opportunity, or is it the sign of a company that’s had its best days? Could be both, depending on which way you look at it. But here’s what I think.
In a post as dramatic as a Gogol novella, 0xngmi unveiled comparative charts for XRPUSDT volume on Aster and Binance, a near-1:1 ratio that would make even the most stoic accountant blush. Hyperliquid, meanwhile, stood apart, its decorrelated profile a beacon of virtue in this sea of suspicion. Yet, Aster, oh Aster, thou dost withhold the lower-level order data, the very key to verifying the genuineness of thy trades! Thus, Defillama, with a heavy heart and a firm hand, hath temporarily banished thee from its hallowed lists. 🧹
According to the parchment filed with the Hong Kong Stock Exchange, this treasure trove of HK$86.7 million ($11.1 million) shall be procured through a share placement to Innoval Capital, a firm nestled in the sun-drenched British Virgin Islands. Innoval, led by the enigmatic Moore Xin Jin, shall acquire 69.38 million new shares at HK$1.25 each, a price that whispers of both opportunity and risk. Jin, whose name carries the weight of managing over $1.6 billion in assets through the Nasdaq-listed Antalpha Platform Holding Company, lends an air of gravitas to this venture. 🧙♂️
Some industries are so soaked in volatility that they’re like a wet cigarette that won’t light. But then there’s the energy sector. Sure, it’s been through the wringer-just like every other sector-but it has a way of bouncing back. It’s not for the faint of heart, but the big players know how to deliver high yields and grow dividends in the thick of it. Look no further than ExxonMobil (XOM) and Enterprise Products Partners (EPD)-two names that have been making waves and paying out for years.
Musk initially announced on Sept. 30 that xAI was building Grokipedia, telling X that it “will be a massive improvement over Wikipedia,” and adding that, frankly, it is a necessary step toward the xAI goal of understanding the Universe. 🌌
Details on the specifics are currently sparse; however, Musk has previously stated that Grokipedia will consist of an “open source knowledge repository.”
